OBJECTIVES: This paper aims to identify clinical and serological differences, damage accrual and mortality, in juvenile, adult and late-onset @entity1252 . METHODS: We conducted our study with @entity1 fulfilling @entity1252 classification criteria taken from the Hospital Gregorio Mara  on Autoimmune Systemic @entity627 ' Registry (1986 to 2012). Clinical characteristics, laboratory data and therapies used during the course of the disease were analysed with @entity1 divided into 3 groups: juvenile-onset ( <=18 years), adult-onset (19-50) and late onset (>50 years). RESULTS: Four hundred and forty-five @entity1 were included. @entity8 and cutaneous manifestations were more frequent in the juvenile-onset group at disease onset. During follow-up, juvenile-onset group presented a higher incidence of @entity8 , @entity1910 , @entity2407 , @entity1333 , and @entity146 manifestations than the other two groups. @entity625 and lymphopoenia were more frequent in the adult-onset group. Arterial @entity101 and @entity5 were more frequent in the late-onset group. Low serum complement, anti-dsDNA, anti- @entity8107 and anti-Sm antibodies were more common in the juvenile-onset group. @entity1 with late-onset @entity1252 had more damage accrual. Thirty-seven @entity1 (8.3%) died during the study. All-cause mortality was significantly higher in the late-onset group. Age at disease onset >50 years was an independent risk factor for damage accrual (OR, 2.2; 95%CI, 1.1-4.6; p=0.029) and mortality (OR, 2.6; 95%CI, 1.1-6.3; p=0.03). CONCLUSIONS: We found significant differences in clinical and serological profiles between juvenile, adult and late-onset @entity1252 . The most significant of which was a higher prevalence of @entity8 as well as different autoantibody signatures for the juvenile-onset group.

Juvenile, adult and late-onset XXXX : a long term follow-up study from a geographic and ethnically homogeneous population.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['neuropsychiatric and renal complications', 'renal disease', 'Renal disease'] @entity627 :: ('MESH:D012216', 'Disease') :: ['Rheumatic Diseases'] @entity625 :: ('MESH:D001168', 'Disease') :: ['Arthritis'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['malar rash'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['cutaneous vasculitis'] @entity146 :: ('MESH:D001523', 'Disease') :: ['neuropsychiatric'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasm'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE'] @entity2407 :: ('MESH:D011928', 'Disease') :: ["Raynaud's phenomenon"] @entity8107 :: ('6625', 'Gene') :: ['U1RNP']
@entity1252 :: (MESH:D008180,Disease) :: ['systemic lupus erythematosus']
